AN2 Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -9,353 | -7,216 | -11,537 | -7,522 |
EBIT | -7,216 | -11,537 | -17,214 | |
Net Income | -9,353 | -6,462 | -10,649 | -7,522 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,375 | -7,599 | -10,624 | -5,273 |
Cash | 18,003 | 18,220 | 19,985 | 21,351 |
Basic Shares | 30,276 | 30,172 | 30,054 | 29,883 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -77 | |||
EBITDA | 3,233 | 4,903 | -43,468 | -21,474 |
EBIT | -51,321 | -64,732 | -42,262 | -21,574 |
Net Income | -51,321 | -64,732 | -41,470 | -21,474 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -49,257 | -53,288 | -33,462 | -20,484 |
Cash | 21,351 | 15,647 | 27,219 | 12,097 |
Basic Shares | 29,828 | 23,600 | 15,340 | 18,740 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.31 |
2025-06-30 | -$0.21 |
2025-03-31 | -$0.35 |
2024-12-31 | -$0.25 |
